Ángel Rodríguez

Ángel Rodríguez

Auto-generated profile, based on publicly available information

Ángel Rodríguez

Eli Lilly and Company Indianapolis Indiana USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in The Lancet
Verified
Journal Article
Closed access
BLBernhard Ludvik
Bernhard Ludvik
FGFrancesco Giorgino
Francesco Giorgino
EJEsteban Jódar
Esteban Jódar
JFJuan P Frias
Juan P Frias
LLLaura Fernández Landó
Laura Fernández Landó
ÁRÁngel Rodríguez
Ángel Rodríguez

8 February 2022 in JAMA
Verified
Journal Article
Open access
PDF file
DDDominik Dahl
Dominik Dahl
YOYukiko Onishi
Yukiko Onishi
PNPaul Norwood
Paul Norwood
RHRuth Huh
Ruth Huh
RBRoss Bray
Ross Bray
ÁRÁngel Rodríguez
Ángel Rodríguez
Quiz Ref ID Basal insulins are widely used in patients with type 2 diabetes and inadequate glycemic control with oral glucose-lowering medications. Although increasing the basal insulin dose often improves glycemic control, it can also be associated with increased risk of hypoglycemia and weight gain, resulting in inadequate intensification of insulin dose in clinical practice.1

22 April 2022 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
Amalia GastaldelliAmalia Gastaldelli
Amalia Gastaldelli
KCKenneth Cusi
Kenneth Cusi
LLLaura Fernández Landó
Laura Fernández Landó
RBRoss Bray
Ross Bray
BBBram Brouwers
Bram Brouwers
ÁRÁngel Rodríguez
Ángel Rodríguez

18 October 2023 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
HPHiren Patel
Hiren Patel
KKKamlesh Khunti
Kamlesh Khunti
HRHelena W Rodbard
Helena W Rodbard
HBHarpreet S. Bajaj
Harpreet S. Bajaj
RBRoss Bray
Ross Bray
ÁRÁngel Rodríguez
Ángel Rodríguez
Aims: To evaluate gastrointestinal adverse events (AEs) and the impact of nausea, vomiting or diarrhoea (N/V/D) and any gastrointestinal (GI) AEs overall on weight change with tirzepatide across the SURPASS‐1 to ‐5 clinical trials. Materials and Methods: Participants with type 2 diabetes were randomized to receive once‐weekly tirzepatide (5, 10 or 15 mg) or comparator (placebo, semaglutide 1 mg once weekly, or titrated daily basal insulins) as monotherapy or added on to background antihyperglycaemic medication(s). This post hoc analysis subdivided participants within each trial into subgroups that self‐reported (yes/no) any N/V/D or GI AEs. Change from baseline in body weight at the primary timepoint was assessed within each trial and subgroup. Mediation analyses were conducted to evaluate the contribution of direct and indirect (mediated by N/V/D or GI AEs) effects of tirzepatide on weight change versus comparators. Results: Across the SURPASS‐1 to ‐5 trials (N = 6263), nausea (12%‐24%), diarrhoea (12%‐22%), and vomiting (2%‐13%) were the most common GI AEs reported with tirzepatide; these were transient and of mild‐to‐moderate severity. Mean weight reduction at the primary timepoint with tirzepatide was consistent between participants who reported N/V/D (−6.2 to −14.9 kg) and those who did not report N/V/D (−6.2 to −13.3 kg). Mean weight reduction was significantly ( P < 0.01) greater with tirzepatide compared with placebo, semaglutide 1 mg, and basal insulins within the N/V/D and GI AEs subgroups. Mediation analyses suggested minimal contribution (<6%) of N/V/D and GI AEs to the overall difference in weight change between tirzepatide and comparators. Conclusions: Superior weight reduction with tirzepatide versus comparators appears to be independent of reported N/V/D or GI AEs.

6 September 2023 in Diabetes Care
Verified
Journal Article
Open access
PDF file
JRJulio Rosenstock
Julio Rosenstock
LVLuis Alberto Vazquez
Luis Alberto Vazquez
SPStefano Del Prato
Stefano Del Prato
DFDenise Reis Franco
Denise Reis Franco
GWGovinda Weerakkody
Govinda Weerakkody
ARAngel Rodríguez
Angel Rodríguez
OBJECTIVE: Tirzepatide is a novel single-molecule glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, which demonstrated unprecedented improvements in glycemic control and body weight reduction, in the SURPASS phase 3 program. In this exploratory analysis, we aimed to characterize tirzepatide-treated participants who achieved HbA1c <5.7% and evaluate changes in clinical markers associated with long-term cardiometabolic health. RESEARCH DESIGN AND METHODS: Baseline characteristics and change from baseline to week 40 for several efficacy and safety parameters were analyzed according to HbA1c attainment category (6.5%) using descriptive statistics in participants taking ≥75% of treatment doses, without rescue medication, in the SURPASS 1–4 trials (N = 3,229). Logistic regression models with tirzepatide doses adjusted as a covariate were used to obtain odds ratios and assess the impact of patient characteristics achieving an HbA1c <5.7%. RESULTS: Tirzepatide-treated participants who achieved HbA1c <5.7% were slightly younger, with a shorter duration of diabetes and lower HbA1c value at baseline compared with those who did not achieve HbA1c <5.7%. In addition, they showed greater improvements in HbA1c, body weight, waist circumference, blood pressure, liver enzymes, and lipid parameters without increasing hypoglycemia risk. CONCLUSIONS: Normoglycemia was unprecedently achieved in a significant proportion of participants in the SURPASS clinical program, without increasing hypoglycemia risk, and was associated with an overall improvement in metabolic health.

11 April 2014 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
FTFrancisco Tinahones
Francisco Tinahones
JGJ. L. Gross
J. L. Gross
AOA. Onaca
A. Onaca
SCS. Cleall
S. Cleall
ARA. Rodríguez
A. Rodríguez
Aims: To compare the efficacy and safety of two insulin intensification strategies in patients with type 2 diabetes inadequately controlled on basal insulin glargine with metformin and/or pioglitazone. Methods: A multinational, randomized, open‐label trial that compared insulin lispro low mixture ( LM25 ; n = 236) twice daily with a basal–prandial regimen of insulin glargine once daily and insulin lispro once daily ( IGL ; n = 240) over 24 weeks in patients with HbA1c 7.5–10.5% and fasting plasma glucose ≤6.7 mmol/l. The primary objective was to assess non‐inferiority [per‐protocol ( PP ) population], and then superiority [intention‐to‐treat ( ITT ) population], of LM25 versus IGL according to change in HbA1c after 24 weeks (non‐inferiority margin 0.4%, two‐sided significance level 0.05). Results: Estimated change [least squares ( LS ) mean (95% CI )] in HbA1c after 24 weeks: −1.30 (−1.44, −1.16)% with LM25 and −1.08 (−1.22, −0.94)% with IGL . Non‐inferiority was shown [ LS mean (95% CI ) HbA1c treatment difference −0.21 (−0.38, −0.04) ( PP population)]; gated superiority assessment showed a statistically significant advantage for LM25 (p = 0.010; ITT population). Mean blood glucose, glycaemic variability, overall tolerability and hypoglycaemic episodes per patient‐year did not show significant differences between treatments during the study. Conclusions: In patients with type 2 diabetes inadequately controlled on once‐daily basal insulin glargine and metformin and/or pioglitazone, intensification with LM25 was superior to a basal–prandial approach in terms of reduction in HbA1c after 24 weeks and did not increase hypoglycaemia episodes.